Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma

Código QR

Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma

Introduction: Development of immune-related adverse events (irAEs) has been associated with enhanced efficacy with the use of immune checkpoint inhibitors (ICIs). It remains unknown whether such an association exists in advanced hepatocellular carcinoma (aHCC). This study aims to evaluate the associ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kennedy Yao Yi Ng, Sze Huey Tan, Jack Jie En Tan, Desiree Shu Hui Tay, Ailica Wan Xin Lee, Andrea Jing Shi Ang, Lawrence Wen Jun Wong, Su Pin Choo, David Wai-Meng Tai, Joycelyn Jie Xin Lee
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	hepatocellular carcinoma immune checkpoint inhibitors immune-related adverse events survival response Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/496d27c9aa9f4d5e9ef0778f2382933a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
por: Marina A. Lyadova, et al.
Publicado: (2021)

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Pan Shen, et al.
Publicado: (2021)

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
por: Rosaria De Filippi, et al.
Publicado: (2021)

A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
por: Yi-Dan Yan, et al.
Publicado: (2021)

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
por: Zoe Apalla, et al.
Publicado: (2021)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
por: Nicola Personeni, et al.
Publicado: (2021)

Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events
por: Rilan Bai, et al.
Publicado: (2021)

Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy
por: Xiujing He, et al.
Publicado: (2021)

Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis
por: Nuttapong Ngamphaiboon, et al.
Publicado: (2021)

Development of a Flow Cytometry Assay to Predict Immune Checkpoint Blockade-Related Complications
por: Hannah-Lou Schilling, et al.
Publicado: (2021)

Identification and Validation of an 6-Metabolism-Related Gene Signature and Its Correlation With Immune Checkpoint in Hepatocellular Carcinoma
por: He Ren, et al.
Publicado: (2021)

Risk factors for immune-related adverse events: what have we learned and what lies ahead?
por: Xiaoyan Liu, et al.
Publicado: (2021)

The roles of exosomal immune checkpoint proteins in tumors
por: Cheng Xing, et al.
Publicado: (2021)

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
por: Xin Cai, et al.
Publicado: (2021)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Nathaniel Wiest, et al.
Publicado: (2021)

Identification of a Pyroptosis-Related Gene Signature for Predicting Overall Survival and Response to Immunotherapy in Hepatocellular Carcinoma
por: Susu Zheng, et al.
Publicado: (2021)

Sarcopenia’s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Donggun Lee, et al.
Publicado: (2021)

Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma
por: Alessandra Lopes, et al.
Publicado: (2018)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Di Wang, et al.
Publicado: (2021)

The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
por: Maria V. Deligiorgi, et al.
Publicado: (2021)

Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
por: Linda Wu, et al.
Publicado: (2021)

CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
por: A. V. Bogolyubova, et al.
Publicado: (2015)

Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report
por: Kin-Sang Lau, et al.
Publicado: (2021)

Integrated analysis on the N6‐methyladenosine‐related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma
por: Yuqin Qiu, et al.
Publicado: (2021)

Pembrolizumab-Induced Lichen Planus on the Scalp of a Patient with Non-Small-Cell Lung Carcinoma
por: Aya Yamashita, et al.
Publicado: (2021)

Predictive Models for HCC Prognosis, Recurrence Risk, and Immune Infiltration Based on Two Exosomal Genes: MYL6B and THOC2
por: Zhu J, et al.
Publicado: (2021)

Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
por: Hong-Bo Li, et al.
Publicado: (2021)

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
por: Xue-lin Zou, et al.
Publicado: (2021)

LRMP Associates With Immune Infiltrates and Acts as a Prognostic Biomarker in Lung Adenocarcinoma
por: Xin Jin, et al.
Publicado: (2021)

Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors
por: Qi J, et al.
Publicado: (2021)

Cardiac MRI in Immune Checkpoint Inhibitor Associated Pericarditis
por: Can Öztürk, et al.
Publicado: (2021)

Progress of Immune Checkpoint Inhibitors  in the Treatment of Advanced Pulmonary Neuroendocrine Tumors
por: Haoqing CHEN, et al.
Publicado: (2021)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Xiaoyin Bai, et al.
Publicado: (2021)

Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC
por: ZHU Kuikui, et al.
Publicado: (2021)

Upregulation of CD47 Is a Host Checkpoint Response to Pathogen Recognition
por: Michal Caspi Tal, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers
por: Brian W. Labadie, et al.
Publicado: (2021)

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
por: Zou W, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in the Large Arteries of Lymphoma Patients under 50 Years of Age
por: Raffaella Calabretta, et al.
Publicado: (2021)

Identification and Validation of Immune-Related Gene for Predicting Prognosis and Therapeutic Response in Ovarian Cancer
por: Zhao-Cong Zhang, et al.
Publicado: (2021)

Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
por: LAI Yanliang, et al.
Publicado: (2021)